S-OA-B
Oral Abstracts - Session B - Allogeneic Transplants & Autologous Transplants
BMT Tandem "Scientific" Meeting
Texas D (Gaylord Texan)
Chairs:
Timothy Fenske, MD
and
Veronika Bachanova, MD
Disclosures:
T. Fenske,
Seattle Genetics, Consultant: Consultancy and Honoraria
V. Bachanova,
Nothing To Disclose
Outcome and Prognostic Factors for Pediatric Patients Receiving an Haploidentical Transplantation Using CD3/CD19 Depleted Grafts
Miguel Angel Diaz, MD, PhD, Hospital Nino Jesus;
Antonio Perez-Martinez, MD; PhD, Hospital Nińo Jesús;
Manuel Ramírez, MD, PhD, Hospital Infantil Universitario Nino Jesus;
Julian Sevilla, MD; PhD, Hospital Nińo Jesús;
Marta Gonzalez-Vicent, MD; PhD, Hospital Nińo Jesús
Risk Factors for Graft Failure and Survival after Reduced Intensity (RIC) Conditioning Allogeneic Hematopoietic Cell Transplantation (HCT) for Myelofibrosis
Brett Glotzbecker, MD, Dana-Farber Cancer Institute;
Haesook T Kim, PhD, Dana-Farber Cancer Institute;
Corey S. Cutler, MD, Dana-Farber Cancer Institute;
John Koreth, MBBS, DPhil, Dana-Farber Cancer Institute;
Philippe Armand, MD, PhD, Dana-Farber Cancer Institute;
Sarah Nikiforow, MD PhD, Dana-Farber Cancer Institute;
Joseph H. Antin, MD, Dana Farber Cancer Institute;
Robert J. Soiffer, MD, Dana-Farber Cancer Institute;
Edwin P. Alyea III, MD, Dana-Farber Cancer Institute;
Vincent T. Ho, MD, Dana Farber Cancer Institute
A Single Nucleotide Polymorphism in the Cytochrome p450 Gene Positively Impacts Survival Post Cyclophosphamide Conditioning in Autologous Transplants for Lymphoma
Veronika Bachanova, MD, University of Minnesota Medical Center, Fairview;
Ryan Shanley, M.S., University of Minnesota;
Linda J. Burns, MD, University of Minnesota;
Jatinder K Lamba, PhD, University of Minnesota;
Lata Chauhan, University of Minnesota
Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation (AutoHCT)
Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute;
Yi-Bin Chen, MD, Massachusetts General Hospital;
Brent R. Logan, PhD, Medical College of Wisconsin;
Görgun Akpek, MD, MHS, Banner MD Anderson Cancer Center;
Xiaochun Zhu, MS, Medical College of Wisconsin;
Hillard M. Lazarus, MD, University Hospitals Case Medical Center;
Christopher N. Bredeson, MD, MSc, The Ottawa Hospital Blood & Marrow Transplant Program;
Richard Olsson, MD, PhD, MMSc, Karolinska University Hospital;
Wael Saber, MD, MS, Medical College of Wisconsin;
Mahmoud D. Aljurf, MD, MPH, King Faisal Specialist Hospital and Research Centre;
Andrew S. Artz, MD, MS, University of Chicago Hospitals;
Philip L. McCarthy, MD, Roswell Park Cancer Institute;
Kenneth R. Cooke, MD, Johns Hopkins University;
Vincent T. Ho, MD, Dana Farber Cancer Institute;
Marcelo C. Pasquini, MD, MS, CIBMTR/Medical College of Wisconsin
A Comparative Study of the Outcome of Isolated Chromosome 13q and Clonal Progression Detected By I-FISH Do Additional Cytogenetic Abnormalities Impact Survival in Multiple Myeloma
Edward Peres, Henry Ford Hospital;
Shatha Farhan, Henry Ford Hospital;
Suseela M Janakiraman, MBBS, Henry Ford;
Phillip Kuriakose, MD, Henry Ford;
Susan Michalowski, PhD, Henry Ford;
Nalini Janakiraman, MD, Henry Ford Health Systems
Impact of Hepatitis B Core Antibody (HBcAb) Seropositivity on the Outcome of High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Laura Biritxinaga, MD Anderson Cancer Center;
Sarah Francesca Jauch, MD Anderson Cancer Center;
Uday R. Popat, MD, The University of Texas MD Anderson Cancer Center;
Mehnaz A Shafi, MD, MD Anderson Cancer Center;
Nina Shah, MD, MD Anderson Cancer Center;
Qaiser Bashir, MD, The University of Texas MD Anderson Cancer Center;
Yvonne Dinh, BS, MD Anderson Cancer Center;
Chitra Hosing, MD, The University of Texas MD Anderson Cancer Center;
Richard E. Champlin, MD, UT MD Anderson Cancer Center;
Muzaffar H. Qazilbash, MD, UT M.D. Anderson Cancer Center
Phase I/II Trial of Lenalidomide and High-Dose Melphalan As Preparative Regimen for Relapsed Myeloma
Muzaffar H. Qazilbash, MD, UT M.D. Anderson Cancer Center;
Peter Thall, PhD, UT MD Anderson Cancer Center;
Patricia S Fox, MS, UT MD Anderson Cancer Center;
Nina Shah, MD, MD Anderson Cancer Center;
Qaiser Bashir, MD, The University of Texas MD Anderson Cancer Center;
Jatin Shah, MD Anderson Cancer Center;
Simrit Parmar, MD, UT M.D. Anderson Cancer Center;
Partow Kebriaei, MD, UT M.D. Anderson Cancer Center;
Yago L. Nieto, MD, PhD, University of Texas MD Anderson Cancer Center;
Yvonne Dinh, BS, MD Anderson Cancer Center;
Uday R. Popat, MD, The University of Texas MD Anderson Cancer Center;
Chitra Hosing, MD, The University of Texas MD Anderson Cancer Center;
Pei Lin, MD, MD Anderson Cancer Center;
Elizabeth J. Shpall, MD, UT MD Anderson Cancer Center;
Robert Z. Orlowski, MD, MD Anderson Cancer Center;
Richard E. Champlin, MD, UT MD Anderson Cancer Center
Long-Term Outcome of Patients with AL Amyloidosis Treated with High-Dose Melphalan and Stem Cell Transplantation: 19 Year Experience at a Single Center
Vaishali Sanchorawala, MD, Boston Medical Center;
Gheorghe Doros, PhD, Boston University School of Public Health;
Karen Quillen, MD, Boston Medical Center;
J. Mark Sloan, MD, Boston Medical Center;
Anthony C Shelton, RN, Boston Medical Center;
Dina Brauneis, NP, Boston Medical Center;
Kathleen T Finn, NP, Boston Medical Center;
David C Seldin, MD, PhD, Boston Medical Center
